Literature DB >> 24569308

Impact of rotavirus vaccine on childhood diarrheal hospitalization after introduction into the South African public immunization program.

Veerle M Y Msimang1, Nicola Page, Michelle J Groome, Jocelyn Moyes, Margaret M Cortese, Mapaseka Seheri, Kathleen Kahn, Meera Chagan, Shabir A Madhi, Cheryl Cohen.   

Abstract

BACKGROUND: Oral rotavirus vaccine was introduced into the South African routine immunization program in August 2009 administered at 6 and 14 weeks with no catch-up. We described the change in rotavirus-associated diarrheal hospitalizations among children <5 years at 3 sentinel sites from 2009 through 2011.
METHODS: During 2009 through 2011, we compared the proportion of enrolled children aged <5 years hospitalized with acute gastroenteritis and testing rotavirus positive. We used hospital data to determine the change in diarrhea hospitalizations and estimated total numbers of rotavirus hospitalizations by adjusting for nonenrolled patients. Stool samples were tested for rotavirus using enzyme immunoassay.
RESULTS: In 2009 (May-December), 46% (404/883) of samples among children <5 years tested rotavirus positive, decreasing to 33% (192/580) (P < 0.001) in 2010 and 29% (113/396) (P < 0.001) in 2011. Compared with May-December 2009, total diarrhea hospitalizations among children aged <5 years was one-third lower in May-December of 2010 and 2011. Among infants, adjusted rotavirus hospitalizations were 61% (n = 267) and 69% (n = 214) lower, respectively, in 2010 and 2011 when compared with 2009 (n = 689), and 45 and 50 percentage points greater than the reduction in rotavirus-negative cases. Among children <5 years, rotavirus hospitalizations were 54% and 58% lower in 2010 and 2011, compared with 2009 (40 and 44 percentage points greater than reduction in rotavirus-negative cases). Rotavirus reductions occurred in rural and urban settings.
CONCLUSION: Using published estimates of rotavirus hospitalization burden, we estimate that at least 13,000 to 20,000 hospitalizations in children <2 years were prevented in the 2 years after rotavirus vaccine introduction.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24569308     DOI: 10.1097/INF.0b013e3182a72fc0

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  26 in total

Review 1.  Overview of the Development, Impacts, and Challenges of Live-Attenuated Oral Rotavirus Vaccines.

Authors:  Olufemi Samuel Folorunso; Olihile M Sebolai
Journal:  Vaccines (Basel)       Date:  2020-06-27

2.  Impact of Rotavirus Vaccination on Hospitalizations and Deaths From Childhood Gastroenteritis in Botswana.

Authors:  Leslie A Enane; Paul A Gastañaduy; David M Goldfarb; Jeffrey M Pernica; Margaret Mokomane; Banno Moorad; Lingani Masole; Jacqueline E Tate; Umesh D Parashar; Andrew P Steenhoff
Journal:  Clin Infect Dis       Date:  2016-05-01       Impact factor: 9.079

Review 3.  Rotavirus vaccines: current status and future considerations.

Authors:  Catherine Yen; Jacqueline E Tate; Terri B Hyde; Margaret M Cortese; Benjamin A Lopman; Baoming Jiang; Roger I Glass; Umesh D Parashar
Journal:  Hum Vaccin Immunother       Date:  2014-04-22       Impact factor: 3.452

4.  Impact of rotavirus vaccine on all-cause diarrhea and rotavirus hospitalizations in Madagascar.

Authors:  V L Rahajamanana; J L Raboba; A Rakotozanany; N J Razafindraibe; E J P R Andriatahirintsoa; A C Razafindrakoto; S A Mioramalala; C Razaiarimanga; G G Weldegebriel; E Burnett; J M Mwenda; M Seheri; M J Mphahlele; A L Robinson
Journal:  Vaccine       Date:  2017-09-25       Impact factor: 3.641

5.  Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa.

Authors:  Myron J Levin; Jane C Lindsey; Susan S Kaplan; Werner Schimana; Jody Lawrence; Monica M McNeal; Mutsa Bwakura-Dangarembizi; Anthony Ogwu; Evans M Mpabalwani; Paul Sato; George Siberry; Margaret Nelson; Darcy Hille; Geoffrey A Weinberg; Adriana Weinberg
Journal:  AIDS       Date:  2017-01-02       Impact factor: 4.177

6.  Temporal association of rotavirus vaccination and genotype circulation in South Africa: Observations from 2002 to 2014.

Authors:  N A Page; L M Seheri; M J Groome; J Moyes; S Walaza; J Mphahlele; K Kahn; C N Kapongo; H J Zar; S Tempia; C Cohen; S A Madhi
Journal:  Vaccine       Date:  2017-10-27       Impact factor: 3.641

7.  Impact and Effectiveness of Monovalent Rotavirus Vaccine Against Severe Rotavirus Diarrhea in Ghana.

Authors:  George Armah; Kimberly Pringle; Christabel C Enweronu-Laryea; Daniel Ansong; Jason M Mwenda; Stanley K Diamenu; Clement Narh; Belinda Lartey; Fred Binka; Scott Grytdal; Manish Patel; Umesh Parashar; Ben Lopman
Journal:  Clin Infect Dis       Date:  2016-05-01       Impact factor: 9.079

8.  Whole genome detection of rotavirus mixed infections in human, porcine and bovine samples co-infected with various rotavirus strains collected from sub-Saharan Africa.

Authors:  Martin M Nyaga; Khuzwayo C Jere; Mathew D Esona; Mapaseka L Seheri; Karla M Stucker; Rebecca A Halpin; Asmik Akopov; Timothy B Stockwell; Ina Peenze; Amadou Diop; Kader Ndiaye; Angeline Boula; Gugu Maphalala; Chipo Berejena; Jason M Mwenda; A Duncan Steele; David E Wentworth; M Jeffrey Mphahlele
Journal:  Infect Genet Evol       Date:  2015-02-17       Impact factor: 3.342

9.  Impact of pentavalent rotavirus vaccine against severe rotavirus diarrhoea in The Gambia.

Authors:  Bakary Sanneh; Alhagie Papa Sey; Minesh Shah; Jacqueline Tate; Mariama Sonko; Sheriffo Jagne; ModouLamin Jarju; Dawda Sowe; Makie Taal; Adam Cohen; Umesh Parashar; Jason M Mwenda
Journal:  Vaccine       Date:  2018-03-12       Impact factor: 3.641

10.  Detection of diarrhoea associated rotavirus and co-infection with diarrhoeagenic pathogens in the Littoral region of Cameroon using ELISA, RT-PCR and Luminex xTAG GPP assays.

Authors:  Rahinatou N Ghapoutsa; Maurice Boda; Rashi Gautam; Valantine Ngum Ndze; Akongnwi E Mugyia; Francois-Xavier Etoa; Michael D Bowen; Mathew D Esona
Journal:  BMC Infect Dis       Date:  2021-06-28       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.